- Research Article
- 10.1016/j.esmoop.2026.106449
142TiP A phase I/II study of EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in advanced RET fusion-positive NSCLC
- Mar 17, 2026
- ESMO Open
- M Aldea + 19 more +19
